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Abstract
Cutaneous T-cell lymphomas (CTCLs) are character-
ized by the recruitment of malignant T-cell clones,
predominantly of the CD4+ T-helper subpopulation, into
the skin. Mycosis fungoides (MF) is the most common
type of CTCL and accounts for almost 50% of all pri-
mary cutaneous lymphomas. The ProteinChip tech-
nology surface-enhanced laser desorption/ionization
time of flight/mass spectrometry (SELDI-TOF-MS) was
used to detect biomarkers in sera from MF patients
(n = 25) and healthy controls (n = 26). Therefore, diluted
sera were applied to IMAC30 ProteinChip arrays, and
the resulting protein profiles were bioinformatically
analyzed. A protein set that distinguishes MF patients
from healthy controls with a sensitivity of 82.6% and
a specificity of 100% was identified. Four significant
peaks were identified by two-dimensional gel electro-
phoresis, immunodepletion, and SELDI-TOF-MS as
transthyretin (TTR) and three TTR modifications. A
subsequent enzyme-linked immunosorbent assay
confirmed these findings. The ability to detect and
identify proteins and protein modifications using
SELDI-TOF-MS might reveal a better insight on this
kind of disease and may lead to a better understanding
and earlier detection of MF patients.
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Introduction
Primary cutaneous T-cell lymphoma (CTCL) comprises a
heterogeneous group of non-Hodgkin’s lymphomas in-
volving memory Tcells, predominantly of the CD4+ T-helper
subpopulation, which preferentially migrate into the skin.
CTCL represents the most common primary cutaneous
lymphoma (65%), whereas mycosis fungoides (MF) rep-
resents the most common disease (50% of all primary cu-
taneous lymphomas), followed by primary cutaneousCD30+
lymphoproliferative disorders (accounting for approximately
30%, including primary cutaneous anaplastic large cell
lymphoma) and the leukemic variant Se´zary syndrome (with
about 3%) [1]. The MF type starts mostly in middle adulthood
and has an incidence of 0.4/100,000 individuals/year in the
United States [2], with increasing ratio. Although treatable in its
early stages, MF is frequently misdiagnosed because of its
similarities to more benign forms of skin diseases. About 25%
of MF patients with extensive patches or plaques will develop
progressive disease. The leukemic variant Se´zary syndrome
is the more aggressive form, with a mean survival of 3 years
from the time of diagnosis and is characterized by the pres-
ence of circulating lymphocytes of cerebriform nuclei (Se´zary
cells) in the peripheral blood, lymph nodes, or skin [3,4]. The
etiology of MF is still unknown, but some viral infections such
as human T-lymphotropic virus type I [5] or Epstein-Barr virus
[6] are proposed.
To date, only a few biomarker candidates have been iden-
tified for this disease. Next to neopterin [7], b2-microglobulin
and soluble IL-2 receptor [8] have been described as pos-
sible candidate markers that are elevated in CTCL patients.
The studies of Hamerlinck et al. reveal an overexpression of
neopterin in the later stage of MF (except Se´zary syndrome),
whereas Hassel et al. described neopterin to be significantly
elevated only in Se´zary syndrome patients. Increased levels
of neopterin [9,10], b2-microglobulin [11,12], or soluble IL-2
receptor [13,14] can be observed in many other malignant
diseases and are not specific to CTCL. Therefore, it is very im-
portant to identify biomarkers that are specific for CTCL pa-
tients and easy to detect.
It has been shown that cDNA microarrays [15] and the
ProteinChip technology surface-enhanced laser desorption/
ionization time of flight/mass spectrometry (SELDI-TOF-MS)
[16] are appropriate tools used to distinguish between MF
patients and control persons. Biomarker discovery with the
SELDI-TOF-MS technique is described both in body fluids such
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as urine, blood, or serum and in microdissected tissues and
cell subfractions of blood [16–18].
In previous studies, we have described our fractionation
strategy using magnetic cell sorting (MACS) for CD4+ and
CD4 lymphocyte preparations to determine differentially
expressed proteins in MF patients and healthy controls. In
the course of these studies, we revealed HNP3 as a bio-
marker candidate for CTCL patients that separates CD4+
and CD4 lymphocytes from healthy controls [16]. The aim of
the current study was the detection of possible biomarkers
in the sera of MF patients, using SELDI-TOF-MS, because
analysis of body fluids is fast and easy to perform. For our
investigation, we examined 25 MF patients vs 26 healthy
controls using IMAC30 ProteinChip arrays.We thereby found
transthyretin (TTR) and its modifications to be diminished
in the sera of MF patients compared to those of healthy con-
trols. We have also been able to detect a peak with a mo-
lecular mass of about 8590 Da in sera, which was found to
be decreased in our previous fractionation studies.
Materials and Methods
Serum Samples
Twenty-five MF serum samples were obtained from
the Department of Dermatology of the Friedrich-Schiller-
University (Jena, Germany). The patients were between
pT1N0M0 and pT4pN3cM0 (stages Ia–IV). As controls, we
used 26 serum probes from healthy donors. All serum sam-
ples were extracted, separated, and stored (80jC) under
the same protocol before use.
ProteinChip Array
The application of IMAC30 ProteinChip array (Ciphergen,
Fremont, CA) was performed according to the manufac-
turer’s instructions. In short, 5 ml of 0.1 M Ni-sulfate was
applied twice to the spots and washed away with water. Five
microliters of binding buffer (0.5 M NaCl) was incubated for
5 minutes. The serum was diluted in binding buffer, and 3 ml
(1.5 mg/ml) was applied to 3 ml of binding buffer on the
ProteinChip. Toward incubation for 90 minutes, the spots
were washed thrice with binding buffer, followed by washing
with water twice. Finally, 0.5 ml of sinapinic acid was added
twice, and the arrays were analyzed with a ProteinChip
Reader (series 4000; Ciphergen).
Bioinformatic Analysis of ProteinChip Array Data
The resulting protein profiles between 2 and 20 kDa were
subjected to CiphergenExpress Client 3.0 software and a
cluster-based and rule-based data mining algorithm (XLminer
3.0; BioControl Jena GmbH, Jena, Germany). CE software
was used for the processing of raw spectra and the calcula-
tion of P values and cluster plots according to the manufac-
turer’s instructions. The data analysis algorithm underlying the
XLminer software consists of three steps: a clustering step, a
rule-extraction and rating step, and a rule-base construction
step, as described elsewhere [19]. The latter two of these
steps are supervised with respect to the given sample classi-
fication (CTCL versus unaffected). Log2-transformed and nor-
malized data were clustered in an unsupervised mode into
two clusters (‘‘low expressed’’ and ‘‘high expressed’’) for each
peak using a modified fuzzy C-means algorithm. Using the
assignment of each sample to these two states (low and high)
as the condition part and the classification outcome (CTCL
and unaffected) as the conclusion part, rules are generated
in the rule-extraction step and rated by a statistically based
rule-rating measure introduced by Kiendl and Krabs [20].
Finally, a small subset of rules from the rule list is assembled
to form a rule base that can be used for the automatic clas-
sification of new patient samples. To classify a new patient
sample, the cluster memberships (condition part of the rules)
of all rules from the rule base that point to the same classifi-
cation outcome (conclusion part of the rules) are added, and
the sample is assigned to the class (classification outcome)
with the highest vote.
Identification of Proteins
To identify the protein with a molecular mass of 13,746 Da
that separates MF patients from healthy persons, we per-
formed two-dimensional gel electrophoresis (2-DE) with both
normal and MF sera. In short, 40 ml of serum was precipitated
in 60 ml of 20% trifluoroacetic acid (TFA) and 50% acetonitrile
(ACN) for 2 hours at 20jC, followed by a 30-minute step at
4jC. After centrifugation (15,000 rpm, 15 minutes, 4jC), pro-
tein pellets were washed twice in ice-cold 80% acetone. After
centrifugation, the pellets were rehydrated overnight in 2%
immobilized pH gradient (IPG) buffer, 0.5% 3-[(3-cholamido-
propyl)-dimethylammonio]-1-propane-sulfonate (CHAPS),
0.2% dithiothreitol (DTT), 8 M urea, and 0.002% bromophenol
blue. Isoelectric focusing (IEF) was carried out using 11-cm
IPG strips and a PROTEAN IEF Cell (Amersham, Piscataway,
NJ). The second dimension was performed using a 4% to a
12% gradient gel (Invitrogen, Carlsbad, CA) in a Novex Mini-
Cell (Invitrogen). Gel staining was proceeded in Coomassie
brilliant blue G-250.
Immunodepletion
About 10 ml of protein A agarose was washed in CoIP
buffer containing 20 mM HEPES, 0.1 mM EDTA, and 50 mM
KCl. Four microliters of anti-human prealbumin antibody
(whole antiserum; Sigma Aldrich, Taufkirchen, Germany)
was coupled and incubated at 4jC for 1 hour. After blocking
with 3%milk powder, the agarose was washed in CoIP buffer,
and 7 ml of 1:50 diluted serum from healthy donors was
added. The supernatant was removed and applied to a Ni-
coated IMAC30 ProteinChip array. The control with IgG anti-
body was treated in the same way.
TTR Enzyme-Linked Immunosorbent Assay (ELISA)
The human prealbumin ELISA kit (Assaypro, Winfield,
MO) was used according to the manufacturer’s instructions
to detect TTR levels in sera. The serum was diluted 1:8000
in enzyme immunoassay (EIA) diluent, and 50 ml was ap-
plied to a 96-well plate and incubated for 2 hours. After
washing, 50 ml of biotinylated TTR antibody was added.
The supernatant was removed, the well was washed, and
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50 ml of streptavidin–peroxidase conjugate was applied. Fi-
nally, 50 ml of chromogen substrate was incubated for 10min-
utes before adding 50 ml of stop solution. Absorbance was
measured immediately with a UVIKON spectrophotometer
(Kontron Instruments) at a wavelength of 450 nm.
Results
ProteinChip Profiling
Twenty-five MF patients and 26 unaffected control sera
were analyzed with a ProteinChip Reader (series 4000;
Ciphergen) on Ni-coated IMAC30 ProteinChips. After mea-
surement and normalization, two MF and two control cases
were excluded from further SELDI analyses because the in-
tensities were too low, which means that the normalization
coefficient was too high to be included in this study. Hereby,
26 signals differentially expressed with P < .05 in a mass
range between 2 and 20 kDa were detected.
Bioinformatic Analysis
The P values of all detected peaks were calculated by the
CiphergenExpress Client 3.0 software. The most differenti-
ating signal between MF and unaffected sera possessed a
molecular mass of 8596 Da (P = 1.17  108). The second
specific signal with a molecular mass of 13,746 Da was
identified as TTR. The distribution of intensities for both
peaks comparing MF patients and controls is shown in Fig-
ures 1A and 2. Due to rule extraction, rating, and rule-base
construction, the bioinformatic tool XL-miner (Biocontrol)
revealed eight signals that, when combined, distinguish very
well betweenMF patients and healthy controls (Table 1). This
signature combination of all eight peaks revealed a sensi-
tivity of 82.6% and a specificity of 100%.
Identification of Differentially Expressed Proteins
To identify the serum proteins differentiating between
MF and healthy persons, 2-DE was performed. A number
of spots in the lower molecular mass range were cut out
from the gel and tryptic-digested. The peptide fingerprints of
tryptic digestion generated by SELDI-TOF-MS were ana-
lyzed using the Internet database http://www.matrixscience.
com/cgi/search_form.pl?FORMVER=2&SEARCH=PMF.
Thus, we could identify the protein TTR (P02766; www.
expasy.org) with a score of 69 and a sequence coverage of
92%. This result correlated verywell to one of the differentially
expressed proteins found by IMAC30 Ni ProteinChip profiling
(13.746 Da; P = 2.91  107) using SELDI-TOF-MS. This
specific signal was found to be downregulated in MF sera.
Figure 1. Distribution of the intensity values of (A) the protein peak at 13,746 Da (identified as TTR; P = 2.91  107) and TTR modifications. (B) Cysteinylated
form of TTR (13,878 Da). (C) CysGly-conjugated TTR (13,921 Da). (D) Glutathionylated form of TTR (14,086 Da).
Figure 2. Distribution of the intensity values of the protein peak at 8596 Da
(P = 1.17  108) for MF patients and healthy controls.
Table 1. Rule Base of the Sera Analyzed by IMAC30 Ni ProteinChips for MF
Patients and Normal Controls.
Condition Conclusion
If expression at the peak is Then
8,596 Da high (> 3.72) Normal
13,746 Da high (> 4.08) Normal
13,878 Da high (> 6.18) Normal
13,921 Da high (> 4.74) Normal
6,664 Da high (> 6.04) MF
8,596 Da low (< 1.54) MF
13,878 Da low (4.54) MF
13,921 Da low (< 3.07) MF
All expression values are log2-transformed. The specificity of the combined rule
base is 100%, and the sensitivity is 82.6% (peaks with molecular masses of
13,746, 13,878, and 13,921 Da were identified as TTR or TTR modifications).
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Immunodepletion of TTR
To confirm the affiliation of TTR with the differentially
expressed protein with a molecular mass of 13,746 Da,
immunodepletion was performed (Figure 3). Next to the
peak representing TTR, three other proteins were found de-
pleted. According to Fung et al., two of them stand for TTR
modifications. The first one, which has a molecular mass of
13,878 Da (P = 4.80  105), is the cysteinylated form;
the second one, which has a molecular mass of 14,086 Da
(P =2.75 105), is the glutathionylated form. The third peak,
which occurred depleted (13,921 Da), was also found to be
differentially expressed (P = 2.07  106) when comparing
MF and healthy control sera. According to Biroccio et al. [21],
this signal belongs to the CysGly-conjugated form of TTR.
ELISA
To validate the differential expression of TTR, ELISA
was performed on 25 MF and 26 normal serum samples ac-
cording to the manufacturer’s instructions. The determined
median concentrations of TTR in the sera from unaffected
controls were 122.98 and 46.04 mg/ml for MF patients
(Figure 4). Due to Swiss Prot declaration, the normal fluctua-
tion of TTR level in the sera was between 100 and 400 mg/ml.
Receiver operating characteristic (ROC) curves were con-
structed for TTR serum concentrations, resulting in an
area under the curve (AUC) of 0.890 (Figure 5). At a cutoff
of 90.14 mg/ml, the sensitivity and the specificity were 80.8%
(confidence interval = 62.1–91.5%) and 92% (confidence
interval = 75–97.8%), respectively.
Discussion
Biomarkers are needed to facilitate the prediction of tumor
progression or the early diagnosis of malignant tumors at
the genomic or proteomic level. In the past years, only a few
biomarker candidates, such as neopterin, soluble IL-2 re-
ceptor, or b2-microglobulin, especially in sera, have been
published for CTCLs [8,22]. However, these potential
markers often lack specificity. Thus, it is important to find
more significant and more specific proteins that might sepa-
rate not only MF from healthy controls but also MF from the
more aggressive leukemic Se´zary syndrome variant.
In this study, we performed protein expression profiling
using IMAC ProteinChip arrays and the SELDI-TOF-MS
technique to compare 25 MF and 26 unaffected control sera.
In the present study, we used 2-DE to identify potential
biomarkers that might bring forward the stage at which MF
is detectable. A few spots were excised from a 2-DE gel, and
one of them could be identified as TTR. Immunodepletion
confirmed the affiliation of TTR with the signal detected in a
prior analysis usingSELDI-TOF-MS.Next to TTR, three other
signals were depleted. These three signals have been al-
ready described as TTR modifications: cysteinylated form
Figure 3. NormalizedProteinChip Array profiles of the immunodepletion assay
from a serum probe. To confirm the affiliation of TTR with the differentially
expressed protein with a molecular mass of 13,746 Da, immunodepletion was
performed. An anti-human prealbumin antibody was coupled to protein A
agarose and, after serum incubation, the supernatant was loaded on an
IMAC30 Ni ProteinChip. Thereby, four proteins were depleted; all of them
represent TTR or TTR modifications (13.74 kDa, TTR; 13.87 kDa, cystein-
ylated TTR; 13.92 kDa, CysGly TTR; 14.08 kDa, glutathionylated TTR). From
left to right: 13.74, 13.87, 13.92, and 14.08 kDa.
Figure 4. Acquired TTR ELISA data are shown in a box plot. The calcu-
lated median TTR concentration is 122.98 g/ml in unaffected controls and
46.04 g/ml in MF patients.
Figure 5. The ROC curve was created, and the AUC reveals a value of 0.890.
At a cutoff of 90.14 g/ml, the sensitivity and the specificity are 80.8%
(confidence interval = 62.1–91.5%) and 92% (confidence interval = 75–
97.8%), respectively.
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(13,878 Da), CysGly form (13,921 Da), and glutathionylated
form (14,086 Da) [21,23]. These posttranslational modifi-
cations were also found to be differentially expressed in
MF patients and healthy controls, with P = 4.80  105, P =
2.07 106, and P = 2.75 105, respectively. The XLminer
analysis of SELDI data revealed a sensitivity of 82.6% and
a specificity of 100%, including the eight most differentiating
peaks (Table 1). A subsequent validation with ELISA con-
firmed the potential of TTR to differentiate between MF and
controls. The sensitivity and the specificity for the TTR as
a single marker, using ELISA, were 80.8% and 92%, respec-
tively, at a cutoff of 90.14 mg/ml. Thus, we are the first to
describe TTR and its modifications as possible biomarkers
for the sera of MF patients. Using this method, we have been
able to detect 26 differentially expressed proteins in MF
patients with P < .05 in a mass range between 2 and 20 kDa.
TTR is the major carrier of serum thyroxine and tri-
iodothyronine. The transport of retinol (vitamin A) through
its interaction with retinol-binding proteins is also facilitated
by TTR. This liver-expressed and liver-regulated protein has
also been published as a possible biomarker in other dis-
eases such as ovarian cancer [25,27], hepatocellular carci-
noma [26], and malnutrition [27].
Whereas Feng et al. and Kozak et al. only described un-
modified TTR as a possible biomarker, we have been able to
identify TTR itself and three TTR modifications as decreased
in MF patients. Comparing our findings to the results of
Kozak et al., we observed a difference in the expression of
a and b hemoglobin (Hb). In contrast to the increased
expression of a-Hb and b-Hb in the early stage of ovarian
cancer [25], we could not detect such an overexpression of
a-Hb and b-Hb. This differential result can be explained with
the increased blood supply of epithelial tumors, such as
ovarian or hepatocellular cancer, in contrast to lymphoma.
Fung et al. examined TTR in breast, colon, ovarian, and pros-
tate cancers compared to healthy controls.Whereas the trun-
cated form of TTR (12.8 kDa) and unmodified TTR (13.7 kDa)
were found to be significantly decreased in colon cancer, all
forms of TTR (truncated, unmodified, cysteinylated, and
glutathionylated) were downregulated in ovarian cancer.
Comparing these findings to our results, the unmodified,
cysteinylated, and glutathionylated TTR forms were also
significantly downregulated in MF patients.
The results of ovarian cancer studies differed from ours
on three points [24,25]. First, we could not detect the trun-
cated form of TTR (12.8 kDa). Second, both a-Hb and b-Hb
were not increased in our studies. Third, we found CysGly
TTR modification to be also downregulated in MF patients. It
might be possible that TTR and its modifications are specific
for MF patients and may reveal a biomarker that is easy
and fast to detect.
Next to TTR, we have found a signal with a 8596-Da mo-
lecular mass that was significantly decreased in MF patients.
In previous studies, we have shown a protein (8565 Da) that
was downregulated in MF patients on CD4+ lymphocyte
MACS fractionation. To date, we do not know whether it is
the same protein because the identification process is still
in progress.
In summary, the combination of these techniques might
not be exclusively used to detect and identify differentially
expressed proteins as serum biomarkers in MF patients
[24,25,28]. In further studies, it might lead to the separation
of the early and late stages of MF, or to the separation of MF
and the more benign forms of CTCL.
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